echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Flt3 inhibitor AML produces CR: talk about off-target activity

    Flt3 inhibitor AML produces CR: talk about off-target activity

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today Aptose Bioscience announced that its multi-kinase inhibitor Luxeptinib (formerly known as CG-806) produced a complete response in the early clinical stage of an acute myeloid leukemia (AML).


    Drug source analysis

    Drug source analysis

    Luxe was originally developed as a reversible BTK inhibitor and its main use is chronic leukemia, but so far it is still a substitute goalkeeper in this arena.


    One potential problem with covalent compounds is the so-called off-target side effects.


    But even patients with off-target side effects of serious diseases such as tumors sometimes can't bear it, and Luxe came into being.


    Off-target activity is one of the main differences between small molecule drugs and biological drugs.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.